Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a
lipase-cleavable Sn 2 taxane phospholipid prodrug using
αvβ3-targeted
v 3-targeted theranostic nanoparticles
Dipanjan Pan
Washington University School of Medicine in St. Louis

Anne H. Schmieder
Washington University School of Medicine in St. Louis

Kezheng Wang
Washington University School of Medicine in St. Louis

Xiaoxia Yang
Washington University School of Medicine in St. Louis

Angana Senpan
Washington University School of Medicine in St. Louis

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Pan, Dipanjan; Schmieder, Anne H.; Wang, Kezheng; Yang, Xiaoxia; Senpan, Angana; Cui, Grace; Killgore,
Kendall; Kim, Benjamin; Allen, John S.; Zhang, Huiying; Caruthers, Shelton D.; Shen, Baozhong; Wickline,
Samuel A.; and Lanza, Gregory M., ,"Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a
lipase-cleavable Sn 2 taxane phospholipid prodrug using αvβ3-targeted theranostic nanoparticles."
Theranostics. 4,6. 565-578. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2918

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Dipanjan Pan, Anne H. Schmieder, Kezheng Wang, Xiaoxia Yang, Angana Senpan, Grace Cui, Kendall
Killgore, Benjamin Kim, John S. Allen, Huiying Zhang, Shelton D. Caruthers, Baozhong Shen, Samuel A.
Wickline, and Gregory M. Lanza

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/2918

Theranostics 2014, Vol. 4, Issue 6

565

Ivyspring

Theranostics

International Publisher

Research Paper

2014; 4(6): 565-578. doi: 10.7150/thno.7581

Anti-Angiogenesis Therapy in the Vx2 Rabbit Cancer
Model with a Lipase-cleavable Sn 2 Taxane Phospholipid
Prodrug using αvβ3-Targeted Theranostic Nanoparticles
Dipanjan Pan1*, Anne H. Schmieder1*, Kezheng Wang1,2, Xiaoxia Yang1, Angana Senpan1, Grace Cui1,
Kendall Killgore3, Benjamin Kim1, John S. Allen1, Huiying Zhang1, Shelton D. Caruthers1, Baozhong Shen2,
Samuel A. Wickline1, and Gregory M. Lanza1
1.
2.
3.

Department of Medicine, Washington University School of Medicine, St Louis, MO 63108, USA.
Radiology Department and Molecular Imaging Center, 4th Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150001, China.
Kereos, Inc., Center for Emerging Technology, St. Louis, MO 63108, USA.

* Equal first author co-contributors.
 Corresponding author: Gregory M. Lanza, MD PhD. Division of Cardiology, Campus Box 8215, 660 Euclid Ave, Washington University
School of Medicine, St. Louis, MO 63108. Tel: 314-454-8813, Fax: 314-454-5265, Email: greg.lanza@mac.com.
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2013.09.03; Accepted: 2014.01.27; Published: 2014.03.11

Abstract
In nanomedicine, the hydrophobic nature of paclitaxel has favored its incorporation into many
nanoparticle formulations for anti-cancer chemotherapy. At lower doses taxanes are reported to
elicit anti-angiogenic responses. In the present study, the facile synthesis, development and
characterization of a new lipase-labile docetaxel prodrug is reported and shown to be an effective
anti-angiogenic agent in vitro and in vivo. The Sn 2 phosphatidylcholine prodrug was stably incorporated into the lipid membrane of αvβ3-integrin targeted perfluorocarbon (PFC) nanoparticles
(αvβ3-Dxtl-PD NP) and did not appreciably release during dissolution against PBS buffer or plasma
over three days. Overnight exposure of αvβ3-Dxtl-PD NP to plasma spiked with phospholipase
enzyme failed to liberate the taxane from the membrane until the nanoparticle integrity was
compromised with alcohol. The bioactivity and efficacy of αvβ3-Dxtl-PD NP in endothelial cell
culture was as effective as Taxol® or free docetaxel in methanol at equimolar doses over 96 hours.
The anti-angiogenesis effectiveness of αvβ3-Dxtl-PD NP was demonstrated in the Vx2 rabbit model
using MR imaging of angiogenesis with the same αvβ3-PFC nanoparticle platform. Nontargeted
Dxtl-PD NP had a similar MR anti-angiogenesis response as the integrin-targeted agent, but microscopically measured decreases in tumor cell proliferation and increased apoptosis were detected only for the targeted drug. Equivalent dosages of Abraxane® given over the same treatment
schedule had no effect on angiogenesis when compared to control rabbits receiving saline only.
These data demonstrate that αvβ3-Dxtl-PD NP can reduce MR detectable angiogenesis and slow
tumor progression in the Vx2 model, whereas equivalent systemic treatment with free taxane had
no benefit.
Key words: lipase-labile docetaxel prodrug, perfluorocarbon, nanoparticles

Introduction
Paclitaxel is a cytoskeletal drug that interacts
with tubulin to corrupt mitotic spindle assembly,
chromosome segregation, and cell division by inhibiting microtubule disassembly. As a consequence,

chromosomes are unable to achieve proper metaphase
configuration and mitotic progression is blocked. The
inability to complete cell division promotes apoptosis
or reversion to a quiescent G0-phase of the cell cycle.
http://www.thno.org
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The rarity of paclitaxel, initially isolated from the Pacific yew, led to synthetic chemical pathway development from which emerged docetaxel, a close
chemical analogue of the index compound with similar biological properties. Taxanes have found clinical
applications as a cytotoxic cancer chemotherapeutic
[1] as well as a stent-delivered inhibitor of restenosis
following angioplasty. [2] In nanomedicine, the hydrophobic nature of paclitaxel has favored its incorporation into many nanoparticle formulations, including into the phospholipid outer membrane of
perfluorocarbon nanoparticles. [3]
Perfluorocarbon (PFC) nanoparticles have been
targeted to a myriad of epitopes for diagnostic imaging and site-specific drug delivery for applications in
atherosclerosis, restenosis, cancer and rheumatoid
arthritis. [4-7] Early comparisons of hydrophobic
drugs, including doxorubicin, paclitaxel, and fumagillin, revealed that fumagillin, a potent anti-angiogenic mycotoxin, was retained best in dissolution studies and was effective in vivo. [8, 9] Unfortunately, fumagillin is not readily available in large
quantities, and it is photochemically unstable. [10-12]
Taxanes are reported to elicit potent anti-angiogenic
effects, particularly at low doses, and the compounds
are readily available and chemically stable. [13]
Preliminary studies in the Vx2 model showed
that paclitaxel incorporated into the outer lipid
membrane of PFC nanoparticles was not effective for
anti-angiogenesis whereas fumagillin was. [14] (Additional file 1: Supplemental Figure 1) In vivo pharmacokinetic studies revealed that both fumagillin and
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paclitaxel included in the PFC nanoparticle lipid
membrane were significantly lost in circulation en
route to the endothelial target cells, with the premature release of the taxane occurring quicker and to a
greater extent than the more hydrophobic fumagillin.
We have reported effective in vivo delivery of
hydrophobic drugs entrapped in the phospholipid
surfactant through a mechanism, we described as
“contact facilitated drug delivery” (CFDD). [9] Tethering of the nanoparticle to the target cell surface facilitated the interaction and hemifusion of the two
lipid membranes, which affords the passive transfer
of the drug and phospholipids from the nanoparticle
surface to the outer leaflet of the target cell membrane.
The drug is then translocated to the inner leaflet
through an ATP dependent mechanism. [15, 16]
CFDD eliminates the need for particle internalization
with subsequent endosomal drug payload escape or
extracellular particle release with diffusion into the
cell. We hypothesized that a phospholipid prodrug
approach that couples the active pharmaceutical ingredient (API) through the Sn 2 acyl position (i.e.,
stereospecific hydroxyl group of the second carbon of
glycerol) would provide a stable membrane complex
in the nanoparticle during circulatory transit to the
target site. Subsequent transfer of the monolayer
components into the target cell membrane would allow cell surface or cytosolic phospholipases to enzymatically cleave the Sn 2 ester and release the drug,
allowing it to diffuse into the cytosol for effect. (Figure 1)

Figure 1. Schematic representation of the concept of the lipase-cleavable Sn 2 phosphatidylcholine docetaxel prodrug: The lipophilic docetaxel prodrug is incorporated into the
phospholipid surfactant, where the drug enters the protective hydrophobic acyl layer. The active pharmaceutical ingredient (API) is protected from premature dissolution into
serum or serum lipase liberation during circulation to the target. The API is delivered to the target cell through a “contact facilitated drug delivery” (CFDD) mechanism wherein
the prodrug exchanges passively into the outer target cell leaflet. The prodrug transfers through an ATP dependent mechanism into the inner cell membrane leaflet, which is
contiguous with the internal cell membranes (except the mitochondria). The prodrug undergoes a region-selective enzymatic cleavage at the Sn 2 site by phospholipases, such as
phospholipase A-2 (PLA-2), but up to 60 endothelial lipases could functionally participate in drug liberation into the cytosol.

http://www.thno.org
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The objectives of the present work were: 1) to
develop and characterize an Sn 2 lipase-labile prodrug
of docetaxel (Dxtl-PD); 2) to demonstrate the stability
of the taxane prodrug in the PFC nanoparticles in the
presence of serum and excess lipase, 3) to demonstrate
the anti-neovascular efficacy of the agent in the rabbit
Vx2 cancer model using magnetic resonance (MR)
angiogenesis molecular imaging, 4) to demonstrate
the efficacy advantage of the integrin-targeted
Dxtl-PD nanoparticle compared with the molar
equivalent dose of Abraxane® given systemically, 5) to
microscopically characterize the impact of targeted
Dxtl-PD on intratumoral apoptosis and cell proliferation.

Materials and Methods
Sn 2 lipase-labile taxane phosphatidylcholine
prodrug synthesis
Docetaxel (AvaChem Scientific), a clinically relevant broad-spectrum anticancer agent, was utilized
in the present study for site-specific anti-angiogenesis
therapy. Docetaxel has a low solubility in water (<0.1
μg/ml) and from the synthetic stand point, chemistries involving esterification of the 2’-hydroxyl group,
which is the most reactive of the hydroxy groups, is
feasible. Any conventional method of protecting a
hydroxy group, such as esterification, can be utilized
to protect this hydroxy group at the 2' position, while
leaving the hydroxy groups at the 7 and 10 positions
free for reaction. For the synthesis of docetaxel prodrug, several coupling methods were attempted that
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included dicyclohexyl carbodiimide (DCC) / dimethylaminopyridine (DMAP), phosphorous pentachloride (PCl5), and 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide/dimethylaminopyridine
(EDCI/
DMAP). A summary of those results are consolidated
into Figure 2. Among these reagents, EDCI/DMAP
was the most efficient approach and produced the
desired compound in 78% yield. (Figure 3) The compound was isolated and purified by preparative thin
layer chromatography (prep-TLC) and the structure
was confirmed by NMR and ESI MS spectroscopy.
Paclitaxel prodrug (Kereos, Inc., St. Louis, MO) was
prepared analogously as illustrated and described in
the Additional file 1: Supplemental Figure 2.
Of note, specific 2’-modification of docetaxel was
drawn from analogy based on the scientific literature
when 1H-NMR spectroscopic studies to confirm the
conjugation at the 2’ position failed to resolve the
overlapping resonating peaks from the neighboring
protons of the tetracyclic 17-carbon (heptadecane)
skeleton. [17] Further, the initial approach to synthesize Dxtl-PD involved coupling chemistries through
deprotected 3’-NH2 group. (Figure 2) Docetaxel was
subjected to hydrolytic deprotection in presence of
formic acid to produce 3’-amine deprotected docetaxel. However, the attempted conjugation of
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
(PAz-PC) through the free amine group resulted in a
complex mixture of products and the desired compound was never isolated.

Figure 2. Summary of the attempted synthetic approaches to docetaxel phosphatidylcholine prodrug.

http://www.thno.org
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Figure 3. Sn 2 Docetaxel Prodrug. (A) Cleavage sites of phospholipase enzymes, PLA2 regiospecifically recognizes the Sn 2 acyl bond of phospholipids; (B) predicted mechanistic
pathways of hydrolysis catalyzed by PLA2; (C) structure of the docetaxel prodrug synthesized in this work; (D) structure of parent molecule docetaxel and depicting different
sites for functionalization and activity. PLA2 = phospholipase A2, PLA1=phospholipase A1.

ανβ3-integrin antagonist homing ligand
The ανβ3-integrin antagonist was a quinalone
nonpeptide developed by Bristol-Myers Squibb Medical Imaging (US patent 6,511,648 and related patents)
and initially reported and characterized as the
111In-DOTA conjugate RP478 and cyan 5.5 homologue
TA145 [18]. PFC nanoparticles present ~300 ligands/particle with an IC50 of 50 pM for the
Mn2+-activated αvβ3-integrin (unpublished data from
Kereos, Inc., St. Louis, MO, USA). Targeting of the
lipid-nanoparticles with this peptidomimetic was
shown to be specific for neovascular endothelial cells
expressing the αvβ3-integrin, PECAM, but not Tie-2 (a
maturity biomarker of stabilized endothelium). [19]

Perfluorocarbon nanoparticle synthesis
incorporating docetaxel-prodrug
Phospholipid-encapsulated
perfluorocarbon
(PFC) nanoparticles (NP) were prepared as a microfluidized suspension of 20% (v/v) perfluoroctylbromide (Exfluor Inc., Round Rock, TX), 2.0% (w/v) of a
surfactant co-mixture, and 1.7% (w/v) glycerin in pH
6.5 carbonate buffer. The surfactant co-mixture of
nanoparticles included: ~ 97.6 mole% lecithin, 0.15
mole% of αvβ3-ligand conjugated lipid and 2 mole%
(3.75 wt%) of the taxane prodrug. An αvβ3-integrin
antagonist
coupled
to
phosphatidylethanolamine-PEG2000 was used for homing angiogenesis. For

MR imaging, the surfactant excluded the taxane prodrug
but
included
20
mole%
gadolinium-DOTA-amide-caproyl-phosphoethanolamine at
the expense of equimolar substitution of phosphatidylcholine in the surfactant commixture (i.e.,
αvβ3-Gd-DOTA NP). Nontargeted (NT) nanoparticles
excluded the homing ligands. The surfactant components for each formulation were combined with the
perfluorocarbon, buffer, and glycerin with pH adjusted to 6.5, and the mixtures were homogenized at
20,000 psi for 4 minutes. The nanoparticles were preserved under inert gas in sterile sealed vials until use.
Upon completion of the synthesis, nanoparticles were
thoroughly characterized by physical-chemical techniques e.g. dynamic light scattering (DLS), electrophoretic potential (zeta) and transmission electron
microscopy (TEM). A typical preparation of
αvβ3-Dxtl-PD NP resulted in: particle size, 214±20 nm;
zeta potential, (ζ) -23±12 mv; and polydispersity index, 0.15±0.5. (Figure 4a,b)

Comparison of docetaxel, docetaxel-prodrug,
paclitaxel, and paclitaxel-prodrug on
endothelial cell proliferation in vitro
Mouse vascular endothelial cells (2F2B) were
plated at 2500 cells/well in media with Angiotensin II
(1nM) for overnight culture at 37°C, 5% CO2. Cells
were treated with paclitaxel, docetaxel, paclitaxel
prodrug, or docetaxel prodrug at 0.5 µg/ml, 1 µg/ml,
http://www.thno.org
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5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml for 1
hour with mild agitation. The treatments were removed; cells were washed three times with PBS; fresh
media was added; and the plates were returned back
to the incubator. Cell proliferation was assayed at 24,
48, and 72 hours. At each time point, 20 µl of Alamar
Blue was added to each well and incubated for 4
hours. The supernatants were transferred to a new
replicate plate for spectroscopic analysis. The original
wells were replenished with fresh media and all
plates were returned to the incubator until the next
time point. The reaction was monitored using a fluorescence plate reader (λex 570nm, λem 585nm) where
the resulting signal is proportional to the number of
viable cells present. Signal intensity from each sample
was normalized to signal from the positive saline
control. Each treatment was replicated three times.

In vitro dissolution stability of
docetaxel-prodrug in PFC nanoparticles
The stability of the Dxtl-PD incorporated at 2
mole% (3.75 wt%) into the surfactant (360mg) of PFC
nanoparticles was evaluated by dissolution in plasma
and buffer over three days in triplicate. Drug-laden
nanoparticles were secured within dialysis tubing
(MWCO=60K, Spectrum Laboratories, Inc.), which
were washed externally to remove possible surface
contamination, and then incubated in 3.5 ml of human
plasma at 37°C for 3 days with constant slow rotation.
The dialysis tube samples were transferred to 3.5 ml
of fresh plasma daily and 200µl of the 3.5 ml dialysate
was injected into a reversed-phase HPLC system
(Waters 600S controller, 626 delivery pump, 717 auto
sampler, and 2487 Dual λ absorbance detector)
through a 0.2 µm syringe filter for analysis of prodrug
release. Dxtl-PD was detected at a wavelength 227
nm. A Grace Vydac C18 column, 4.6 x 250 mm, was
used with a mobile phase consisting of: (A) 80% acetonitrile, 20% methanol and (B) 100% 0.2 M ammonium acetate, pH 4.5 using gradient conditions (from
100% A to 40% A 60% B within 30 min then returning
to 100% A in 5 min for an additional 5 min (run time
40 min; drug retention time ~33 min). Flow rate was 1
ml/min.
To further assess the potential susceptibility of
Dxtl-PD in PFC nanoparticles to premature lipase
liberation, drug-laden nanoparticles (250 µl) were
incubated for 24 hours with 3.5 ml fresh plasma or
fresh whole blood preserved with EDTA each spiked
with 250 µl 0.9 % NaCl, 15-30 mM CaCl2 and 0.278 mg
phospholipase A2. This was referenced to an
equimolar amount of Dxtl or Dxtl-PD in DMSO diluted in 3.5ml of PBS pH 7.4. The samples were continuously agitated on a nutator to prevent settling. As
a positive control, 250 µl 2-propanol was added to the
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lipase-spiked plasma containing Dxtl-PD in PFC nanoparticles to “crack” the emulsion’s integrity, exposing the lipase-labile prodrug to the enzyme-rich
plasma milieu. The plasma-enzyme-NP mixture (250
µl) was combined with 250 µl Cleanascite™ for lipid
removal and clarification (Biotech Support Group,
Inc., Monmouth Junction, NJ) at 25°C for 15min. The
mixture was centrifuged at 5000 rpm (30 min) and the
supernatant (200 µl) was analyzed by HPLC.
To determine the potential exchange of Dxtl-PD
from the nanoparticle surfactant to erythrocyte
membranes, 2-propranolol (200 µl) and water (200 µl)
were added to the erythrocyte aliquot (100 µl) and the
mixture was centrifuged at 1000 rpm for 10 min. The
RBC fraction was separated from the pelleting PFC
nanoparticles (specific gravity of 2). The RBC fraction
was analyzed in triplicate for the Dxtl-PD and its
major metabolites by HPLC.

Docetaxel-prodrug testing in vitro:
cytotoxicity and metabolic assays
Mouse endothelial cells (2F2B; ATCC®
CRL2168™, Manassas, VA) were seeded on a 96 well
plate (2000-5000 cells/well) in Dulbecco’s Modified
Eagle’s Medium (DMEM) with 4.5 g/L glucose;
L-glutamine; and 10% heat-inactivated fetal bovine
serum plus 10 µM angiotensin II (Sigma Chemical Co,
St. Louis, MO) and incubated at 37ºC with 5% CO2.
After 24 hours, cells were incubated for 1 hour with 1)
αvβ3-Dxtl-PD NPs, 2) equimolar equivalent of Taxol®
(0.3 µM), 3) αvβ3-No drug NPs, or 4) saline. After incubation the wells were washed three times with PBS
and returned to the incubator. At 96 hours after drug
exposure, cell proliferation was measured using the
MTT assay for cytotoxicity, which measures the activity of cellular enzymes that reduce the tetrazolium
dye, MTT, to the insoluble formazan (Invitrogen;
Carlsbad, CA, USA). Each treatment was replicated 6
times.
In a confirmatory experiment using human endothelial cells (HUVEC; Lonza Walkersville, MD,
USA), cell metabolic activity was assessed using a
Vybrant Cell Metabolic Assay Kit (Invitrogen). The
experiment was conducted as described above with 6
replicates/treatment and measurements assessed at
48, 72, and 96 hours. The treatments applied were:
αvβ3-Dxtl-PD NPs, free Dxtl in methanol (0.3 µM) and
αvβ3-No drug NPs. This assay is based on the reducto
tion
of
non-fluorescent
C12-resazurin
red-fluorescent C12-resorufin in metabolically active
cells, which is attributed to different oxido-reductase
enzyme systems that use NAD(P)H as the primary
electron donor. The redox reaction was monitored
using a fluorescence plate reader (λex 570nm, λem
587nm) where the resulting signal is proportional to
http://www.thno.org
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the number of viable cells present. Signal intensity
from each sample was normalized to signal from the
positive control (αvβ3-targeted no drug nanoparticles).

Docetaxel-prodrug evaluation in rabbit Vx2
tumor angiogenesis model
All animal studies were conducted in accordance
with a protocol approved by the Washington University Animal Studies Committee.

Surgical preparation
The anti-angiogenesis effects of Dxtl-PD were
evaluated in the Vx2 rabbit tumor model using MR
angiogenesis imaging and histology. Male New Zealand White rabbits (~2 kg) were anesthetized with
intramuscular ketamine and xylazine. One hind leg
was shaved, prepped under sterile conditions, and
infiltrated with Marcaine. A 2-3 mm3 rabbit Vx2 tumor fragment (squamous cell carcinoma, National
Cancer Institute Tumor Repository, Frederick, MD,
USA) was implanted at a depth of approximately 0.5
cm through a small incision into the popliteal fossa.
Anatomical planes were closed and secured with a
single absorbable suture. The skin was sealed with
Dermabond skin glue. Animals were recovered by
reversing the effect of ketamine and xylazine with
yohimbine.

Experimental Design
On days 9, 12 and 15 post tumor implantation,
rabbits were treated with either: αvβ3-Dxtl-PD NP,
non-targeted Dxtl-PD NPs, or αvβ3-targeted no drug
NPs at a 2ml/kg i.v. dose. On day 17, rabbits were
imaged in a clinical 3T MR scanner (Philips Achieva)
with an 8-element SENSE coil using a high-resolution,
T1-weighted, fat suppressed, 3D gradient echo sequence (TR/TE = 42/5.7ms, 45o flip angle, 2 NSA, 0.25
x 0.25 x 0.5 mm resolution). Images were obtained
before and 3 hours after i.v. administration of
αvβ3-Gd-DOTA NP (1ml/kg) to compare the influence of the three treatments on angiogenesis. At each
time point, rabbits were anesthetized with 1% to 2%
Isoflurane in oxygen to effect. In a second cohort of
rabbits (n=4/group), the anti-angiogenesis effect of
serially administered Abraxane® at the same drug
dose and days of treatment described above were
compared to an analogously treated saline control.
MRI molecular imaging of tumor volumes and angiogenesis as well as image post processing were performed as described.

Image analysis
In each experiment, the signal intensities of the
MR images were analyzed with MATLAB software
(The Math Works, Natick, MA, USA). Dynamic
T1-weighted signal intensities were normalized to a
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Gd-DTPA doped water reference standard included
within each imaging field-of-view. For each animal, a
region-of-interest (ROI) was manually placed around
the tumor edge on each baseline slice, and the standard deviation of the average tumor signal at baseline
was calculated. Voxels on post-injection MRI images
were defined as enhanced if the signal intensity exceeded the mean tumor signal at baseline by more
than three standard deviations. The tumor ROI was
automatically partitioned into a rim and core region
using an automated erosion method developed in
MATLAB. The core region was set to approximately
half of the ROI volume. The volume of enhancement
was calculated, as well as the relative distribution of
enhancing voxels in the periphery versus the core of
the tumor. High-resolution 3D tumor reconstructions
were created in MATLAB to map the spatial distribution of enhancing neovasculature in each treatment
group. The overall 3D structure of the tumor was
displayed as a mesh surface plot using isosurface
rendering and a smoothing filter. A surface plot of the
enhancing voxels was reconstructed similarly, and
overlaid onto the tumor volume.

Histology
Immediately after MR imaging, animals were
euthanized, and tumors were resected, weighed, and
frozen in optimum cutting temperature (OCT) compound. Tumors (n=4/treatment group) were sectioned and stained for cell proliferation (proliferating
cell nuclear antigen, PCNA) antibody; Abcam, Cambridge, MA, USA) and apoptosis (TUNEL assay;
Promega, Madison, WI, USA) to corroborate MR results. Microscopic images (40x) were obtained with an
Olympus BX61 microscope, Color-view CCD Camera
and analyzed with ImageJ software using manual
placement of regions of interest on each microscopic
image (National Institute of Mental Health, Bethesda,
Maryland, USA.).

Statistical Analysis
Data were analyzed using analysis of variance
(SAS Inc.; Cary, NC, USA) (p < 0.05). Data are presented as the mean ± standard error of the mean unless otherwise stated.

RESULTS
Stability of docetaxel-prodrug in
perfluorocarbon nanoparticles during
dissolution
The retention of the Dxtl-PD in the PFC nanoparticle during in vitro dissolution over 3 days in PBS
with albumin or human plasma was excellent with <
6% of prodrug released, indicating that the drug was
sufficiently membrane stable. (Figure 4c) Phosphohttp://www.thno.org
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lipases A2 (PLA2s) EC 3.1.1.4, commonly found in
mammalian tissues, specifically recognizes the Sn 2
acyl bond of phospholipids and regioselectively hydrolyzes the bond, releasing free fatty acid and lysophospholipids. The catalytic mechanism of PLA2 is
presumably initiated by a His-48/Asp-99/calcium
complex within the active site in the presence of calcium or other small cations like cobalt and nickel. A
simplistic mechanism of catalytic action of PLA2 on
Dxtl-PD has been proposed in Figure 3. Figure 4d
illustrates the HPLC reference retention time of
Dxtl-PD (~32min). In the presence of excess lipase,
Dxtl-PD nanoparticles had nearly negligible release of
the drug (Figure 4e). Incubation of the Dxtl-PD nanoparticles in whole blood under slow continuous
agitation revealed that the prodrug was not passively
transferred to erythrocytes by transient contact (Additional file 1: Supplemental Figure 3). Supplemental Figure 4 shows the relative retention times of
free docetaxel, Dxtl-PD, and the metabolism of
Dxtl-PD in methanol added to phospholipase enriched plasma. As expected, docetaxel retention was
somewhat less than the HPLC retention of Dxtl-PD.
When Dxtl-PD was added to lipase rich plasma,
docetaxel was liberated and differentiated from the
parent prodrug. Regioselective hydrolysis of the pro-
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drug by lipase in vitro required the addition of
2-propranol to “crack” the nanoparticle and expose
the membrane components to the enzyme. The appearance of multiple peaks around 30 minutes
showed that the Dxtl-PD was released and hydrolyzed from the prodrug backbone. (Figure 4f) While
the 32.5 minutes corresponded to intact Dxtl-PD, the
peak at 26.5 minutes in the presence of enzyme was
confirmed by MS to be a hydrolyzed product, baccatin
III [m/z 524 (M+Na)], (Figure 3). The cleavage of the
side chain at C-13 of the taxane ring is known in the
literature and also results in the formation of baccatin
III in rats and is formed as a minor species in humans.
[20, 21]
Collectively, these results suggest that Dxtl-PD
is snuggled into the hydrophobic membrane and
protected from hydrolysis and lipase activation in
plasma until the nanoparticle is destabilized, such as
with alcohol. Over the relatively brief time course of
systemic targeting, αvβ3-Dxtl-PD NP retention of drug
is anticipated to be very high, as opposed to earlier
results with free paclitaxel dissolved into the surfactant, with negligible passive transference to
co-circulating erythrocytes.

Figure 4. Characterization of docetaxel prodrug (Dxtl-PD) loaded PFC nanoparticles (NP). (A) Number-averaged hydrodynamic diameter distribution of αvβ3-Dxtl-PD in
hydrated state; (B) transmission electron microscopy (TEM) image of the integrin targeted nanoparticles (scale bar: 200 nm); (C) dissolution of Dxtl-PD over 3 days when
incubated in PBS with albumin (red) or human plasma (green); HPLC traces of Dxtl-PD (D), Dxtl-PD-NP treated with PLA2 (E) and Dxtl-PD-NP “cracked” with isopropanol and
exposed to PLA2. PLA2=phospholipase A2.

http://www.thno.org
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Bioequivalence of docetaxel, paclitaxel,
docetaxel prodrug, and paclitaxel-prodrug
The bioequivalence of paclitaxel, docetaxel,
paclitaxel prodrug, or docetaxel prodrug at 0.5 µg/ml,
1 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml
was studied in angiotensin II stimulated mouse vascular endothelial cells (2F2B). Monitoring of the proliferative response of these endothelial cells to the
varying doses of drugs at 24, 48 and 72 hours post
exposure reveal no significant difference in anti-endothelial cell proliferation. (Figure 5)

In vitro cytotoxicity and metabolic assays

Figure 5. Mouse vascular endothelial cells (2F2B) stimulated with angiotensin II
(1nM) were treated with paclitaxel, docetaxel, paclitaxel prodrug, or docetaxel
prodrug at 0.5 µg/ml, 1 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml for 1 hour.
Cultures were monitored for proliferation at 24, 48, and 72 hours. No difference (p=
NS) in biopotency of the different taxane forms was detected.

The cytotoxicity of Dxtl-PD incorporated into
PFC NPs was compared to Taxol® in vitro using 2F2B
endothelial cell cultures stimulated with angiotensin
II to up-regulate activated αvβ3-integrin expression.
αvβ3-Dxtl-PD NPs decreased (p<0.05) cell proliferation 34% at 96 hours compared to the saline control,
showing that the drug retained bioactivity through
the prodrug synthesis, and that the compound was
effectively transferred from the particle, into the cell
membranes from where it was liberated in adequate
concentrations to induce cell cytotoxicity. (Figure 6a)
The αvβ3-no-drug NPs had no effect on cell proliferation. At the equivalent low dose of taxane, the Taxol®
treatment decreased cell proliferation less, 8%, which
was more similar to the controls but not significantly
less than the αvβ3-Dxtl-PD NP. The slightly greater
effectiveness of the Dxtl-PD is related to the number
of drug laden nanoparticles bound to the endothelial
cells through the integrin receptor within the brief
incubation window versus the amount of free
paclitaxel able to permeate the cell. (Figure 6a)

Figure 6. A) Cell proliferation via MTT assay comparing docetaxel prodrug targeted to angiotensin II activated integrin receptor in 2F2B endothelial cells versus Taxol® and no
drug targeted particles. At 96 hours, the prodrug was significantly (p < 0.05) more effective than the control and at least equivalent to Taxol®. B) Cell proliferation via Vybrant
Cell Metabolic Assay comparing docetaxel prodrug in HUVEC endothelial cells versus docetaxel in methanol and no drug targeted particles. Marked and equivalent reductions
in cell proliferation were appreciated at 48, 72, and 96 hours with free drug and the integrin targeted Dxtl-PD NPs. * p<0.05.
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In a follow up experiment using angiotensin II
stimulated HUVEC cells, cell metabolic activity responses to nanoparticle delivered docetaxel were assessed at earlier time points: 48, 72, and 96 hours.
(Figure 6b) In this experiment native docetaxel in
methanol added to the medium was compared to its
integrin targeted lipase-labile prodrug analog on an
equimolar drug basis. The treatments applied were:
αvβ3-Dxtl-PD NPs, free Dxtl, and αvβ3-no drug NPs.
As shown in Figure 6b, the nanoparticle delivered
docetaxel prodrug or parent compound equivalently
decreased (p<0.05) cell metabolic activity at 48 hours
when compared with the targeted no-drug nanoparticle control. The marked reductions in cell metabolic
activity persisted for both drug forms at 72 and 96
hours. These results substantiate the comparable bioequivalence of the native docetaxel and targeted Sn 2
lipase-labile prodrug in angiotensin II activated endothelial culture. These data further suggest that the
intracellular enzymatic hydrolysis requirement to
achieve efficacy of Dxtl-PD was not limiting in the
activated HUVEC cells.

Docetaxel prodrug evaluation in rabbit Vx2
tumor angiogenesis model
In a previously unpublished pilot study, the effectiveness of paclitaxel incorporated into the membrane of αvβ3-targeted PFC nanoparticles was evaluated in the Vx2 tumor model (Additional file 1: Supplemental Figure 1). The results showed that serial
doses of the agent produced neither anti-neovascular
nor anti-tumor benefit when evaluated by MR molecular imaging with αvβ3-paramagnetic PFC nanoparticles. Studies simultaneously tracking the perfluorocarbon core, paclitaxel, and homing ligand in
whole blood from rats showed that the particles were
intact but the drug was rapidly and prematurely loss
from the lipid membrane (Kereos, St. Louis, unpublished data).
In the present study, the efficacy of the docetaxel
Sn 2 prodrug incorporated into the lipid membrane of
αvβ3-targeted PFC nanoparticles (αvβ3-Dxtl-PD NP)
was compared in the Vx2 rabbit tumor model to
non-targeted Dxtl-PD NPs (NT-Dxtl-PD NP) and
αvβ3-No Drug NPs. Animals were serially treated on
days 9, 12, and 15 days post implant. On day 17, rabbits were imaged in a clinical 3T MR scanner (Philips
Achieva) using a high-resolution, T1-weighted, fat
suppressed, 3D gradient echo sequence at baseline
and 3 hours after i.v. administration of
αvβ3-Gd-DOTA nanoparticles (1ml/kg), previously
characterized and demonstrated in vivo.
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As previously reported, angiogenesis contrast in
the control animals was concentrated in the tumor
periphery with minimal signal enhancement localized
to the core, except for the rare lobulated tumor with
an internal segment of neovascular-rich capsule.
(Figure 7a,c,d) The peripheral distributions of contrast-enhanced voxels (i.e., 3 standard deviations
greater than baseline) in the control were typically
confluent and asymmetrically distributed, presumably reflecting the most active regions of tumor growth
at the time of imaging. αvβ3-Dxtl-PD NPs substantially decreased (p<0.05) MR detectable angiogenesis
in the Vx2 tumor model after serial treatment, as opposed to the negative results achieved previously
with the targeted particles incorporating native
paclitaxel. (Figure 7b,c,d) The magnitude of neovascular suppression achieved with NT-Dxtl-PD NP was
similar to the results obtained with αvβ3-Dxtl-PD NP,
suggesting that the passive entrapment of the frequently dosed NT-Dxtl-PD NP within the irregular
neovascular bed provided enough sustained particle-endothelial cell contact to afford prodrug transfer,
at least to the extent detectable by MR molecular imaging. We have previously shown with dynamic MR
imaging in the Vx2 rabbit tumor [24] and mouse
melanoma [25] models, that passive entrapment of
nontargeted paramagnetic PFC nanoparticles within
the tumor peripheral neovasculature is detectable
with approximately half the level of contrast signal
observed with αvβ3-targeted paramagnetic particles at
two hours. No differences in tumor volume between
any treatment group were measured. (Additional file
1: Supplemental Figure 5)
To verify that the neovascular effect of the
Dxtl-PD NP, appreciated by MR molecular imaging,
was not attributable to the systemic premature release
of taxanes in one or both groups, a separate cohort of
rabbits implanted with the Vx2 tumor were treated
serially with Abraxane® given at an equimolar dose
and compared to a saline control. MR molecular imaging of angiogenesis with αvβ3-Gd-DOTA nanoparticles on day 17 revealed no anti-angiogenic effectiveness in the Abraxane® treated rabbits versus the
controls. (Figure 8) In fact, the magnitudes of neovascular contrast measured in each group were nearly
identical, as were the tumor volumes (Additional file
1: Supplemental Figure 6). These results demonstrate
that the retention and delivery method of Dxtl-PD in
the nanoparticle was essential to elicit the MR
measureable change in tumor neovasculature.
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Figure 7. A) T1w MR images of Vx 2 tumor obtained at baseline and 3 hours after αvβ3-Gd-DOTA NP in animals receiving αvβ3-no drug NP showing peripheral tumor
angiogenesis contrast enhancement false colored in yellow. B) The same image sequence as panel A in Vx2 tumor rabbits following αvβ3-Dxtl-PD NP. C) Histogram illustrating
marked angiogenesis in the control rabbits rim (tumor peripheral 50%) versus those receiving Dtxl-PD with or without targeting. Note minimal contrast signal with the tumor
core. Marked decrease in contrast in nontargeted (NT) animal group suggests that the dosage or frequency of treatment was in excess of the therapeutic need with passive
entrapment providing adequate particle-to-endothelium contact to afford significant anti-angiogenesis. D) Representative 3D neovascular maps of Vx2 tumor in control and
targeted Dxtl-PD treatment groups. Note asymmetric distribution of confluent neovascular regions in the control rabbit was not appreciated in the treated animal. Blue voxels
equate to αvβ3-Gd-DOTA NP contrast enhancement exceeding 3 standard deviations over baseline. * p<0.05, ** p<0.01.

Figure 8. Vx 2 tumor angiogenesis following serial dosages of Abraxane® (equivalent
to treatment regimen used in Figure 7) versus control rabbits receiving saline as
assessed by MR molecular imaging with αvβ3-Gd-DOTA NP. No effect of the free
taxane drug was detected, which was equivalent to the results previously obtained
with free Taxol® in the preliminary data (Additional file 1: Supplemental Figure
1).

Histological assessments of tumor showed that
αvβ3-Dxtl-PD NP decreased (p<0.05) tumor cell proliferation, as assessed by PNCA staining of the lesion.
(Figure 9c,d) The same trend was measured for tumor
apoptosis. (Figure 9a,b) In each case, the patterns of
staining appeared as patchy confluencies, distributed

variably among animal tumors. These data suggest
that targeted delivery of Dxtl-PD was biologically
more effective than NT Dxtl-PD treatment, which is
consistent with previously reported dynamic imaging
results discussed above. [24] [25] Further, while MR
angiogenesis imaging is able to robustly track the
progression of Vx2 tumor neovasculature around 12
days post implantation or longer, MR sensitivity may
permit only assessment of the macroscopic changes of
neovasculature and may not adequately resolve microscopic differences in neovasculature which may
still impart significant tumor biology impact. Changes
in microvasculature counts following theranostic anti-angiogenesis treatment were correlated previously
with MR molecular imaging of angiogenesis in atherosclerotic rabbits[26], However, given the extensive
heterogeneity of angiogenesis presentation in the tumor, replication here would require complete serial
sectioning
and
quantification
of
neo/microvasculature to compare the extent of microscopic angiogenesis persisting with and without
integrin-targeting, and was precluded in this project.
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Figure 9. A) Histogram showing a trend (nonsignificant (NS), p = 0.2) toward increased apoptosis among Vx 2 tumor rabbits receiving αvβ3-Dxtl-PD NP versus controls. B)
Illustrative sections (40x) of Vx 2 tumor following TUNEL staining (brown arrows) using a methyl green nuclear positive reference for tumor area (green arrows). C). Histogram
showing a significant (p < 0.05) decrease in proliferation index among Vx2 tumor rabbits receiving αvβ3-Dxtl-PD NP versus controls. D) Representative sections (40x) of Vx2
tumor following PCNA staining (brown arrows) using a methyl green nuclear positive reference for tumor area (green arrows). * p < 0.05.

Discussion
The facile synthesis, development and characterization of a new Sn 2 lipase-labile docetaxel prodrug is reported and shown to be an effective anti-angiogenic agent in vitro and in vivo. The Sn 2
phosphatidylcholine drug stably incorporated into
the nanoparticle lipid membrane and did not appreciably release during dissolution against PBS buffer or
plasma over three days. Further, overnight exposure
of αvβ3-Dxtl-PD NP to plasma spiked with phospholipase enzyme failed to liberate the taxane from the
membrane, unless the nanoparticle itself was first
“cracked” with alcohol. The bioactivity and efficacy of
Dxtl-PD was demonstrated in endothelial cell culture
and found to be equivalent to docetaxel, paclitaxel,
and paclitaxel prodrug. The effectiveness of
αvβ3-Dxtl-PD NP was at least as effective as Taxol® at
equimolar doses over 96 hours, with 4-fold numerical

advantage noted for the prodrug over the free compound. At earlier time points, in vitro cell metabolism
studies demonstrated that free docetaxel had equivalent efficacy to αvβ3-Dxtl-PD NP, indicating that requisite intracellular lipase liberation of docetaxel did
not limit prodrug effectiveness at 48 hours, and this
result persisted through 96 hours. The effectiveness of
αvβ3-Dxtl-PD NP compared with the negative control
was demonstrated in the Vx2 rabbit model using MR
molecular imaging of angiogenesis. Nontargeted
Dxtl-PD nanoparticles had a similar anti-angiogenic
response as measured with MR molecular imaging,
indicating that passive entrapment of the particles in
the tumor neo-/microvasculature was adequate to
decrease MR detectable neovasculature. However,
histology of these tumors revealed that αvβ3-Dxtl-PD
NP impacted tumor progression and apoptosis, which
was not appreciated for NT Dxtl-PD NP or the control
groups. Abraxane® given at an equimolar drug doshttp://www.thno.org
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age and frequency as the αvβ3-Dxtl-PD NP had no
effect on angiogenesis when compared to control
rabbits receiving saline only, confirming that the effectiveness of this low taxane exposure was dependent on nanoparticle delivery and concentration at the
tumor.
Dxtl-PD was not incorporated into the
αvβ3-Gd-DOTA nanoparticles to support simultaneous imaging and therapy serially as previously reported in other models. [22] In a previous time course
study characterizing MR angiogenesis mapping in the
Vx2 tumor on days 9, 12, and 15 post tumor implantation, MR molecular imaging was unable to delineate
and differentiate a coherent neovascular pattern or
increased integrated MR contrast signal between
animals receiving αvβ3-Gd-DOTA PFC NPs or
NT-Gd-DOTA PFC NPs on day 9. Although angiogenesis is well known to occur robustly at a microscopic level as tumors grow beyond 2 to 3 mm, the
insensitivity of MRI, even using a strong molecular
imaging agent such as αvβ3-Gd-DOTA PFC NP, was
unable to differentiate specific neovascular targeting
from passive nontargeted entrapment in the Vx2 tumor neo/microvasculature on day 9 post implantation. [23] However, on days 12 and 15 of that study,
clear differences in neovasculature signal were measured between the two groups and a very close correspondence between the neovasculature pattern determined on day 12 and day 15 in the same animal
was illustrated. [23] Consequently, the pursuit of
theranostic MR molecular imaging approach beginning on day 8 post-implantation as a baseline imaging
reference, as demonstrated in other experimental
models[22], was precluded and a companion diagnostic design with serial treatments followed by terminal imaging measurement was adopted.
The direct targeting and delivery of low dose
docetaxel to nascent endothelial cells is a distinctly
different mechanism of achieving anti-angiogenesis
treatment than the vascular endothelial growth factor
(VEGF) inhibitors approved to date. Certainly, tumor
angiogenesis is a complex process with a dominant
role attributed to VEGF. Bevacizumab, anti-VEGF-A,
was initially intended to block angiogenesis and vascular permeability by adsorbing VEGF-A in the tumor
milieu. However, VEGF-A is produced not only by
the tumor but also by surrounding stromal cells, such
that monotherapy with the drug was unsuccessful.
Ultimately, bevacizumab was approved as the first
inhibitor for combination use in metastatic colorectal
cancer [27], then later for non-squamous, non-small
cell lung cancer [28], renal cell carcinoma [29], and
glioblastoma multiforme [30]. Several other
VEGF-directed drugs have followed which competitively inhibit the intracellular ATP at the catalytic
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binding site of tyrosine kinases, including sunitinib
(Pfizer), pazopanib (Glaxo-Smith-Kline), sorafenib
(Nexavar), vandetanib (Astrazeneca), carbozantinib
(Exelixis), axitinib (Inlyta), and linifanib (Abbott).
Tyrosine kinase inhibitors (TKI) are designed to
blockade the downstream signaling pathways that
promote tumor growth and metastasis when stimulated by angiogenic factors. The third class of current
anti-angiogenesis inhibitors impact mTOR, mammalian target of rapamycin, which, under upstream control via the PI3K/AKT pathway, influences cell
growth by modulating metabolism, protein synthesis,
and autophagy. Rapamycin and its analogs, temsirolimus (CCI-779) and everolimus (RAD001), are allosteric inhibitors of mTORC1. In general, these agents
have had limited effectiveness because they are specifically directed to mTORC1, and a second mTOR
(mTORC2) is able to exert negative feedback to
AKT/PKB that can antagonize the anti-tumor effects
of the rapalogs. Resistance to all of these drugs may
result from negative feedback, invocation of alternative angiogenic pathways that circumvent the blockade, selection pressure for tumor or stem cells able
survive the hypoxic environments, induction of cryoprotective tumor cell autophagy or dormancy, or
tumor extravasation to better environs. The nanomedicine approach with αvβ3-Dxtl-PD NP is independent of how the neovasculature expansion is
stimulated to occur, and the endothelium, which is a
normal replicating cell, as opposed to the epigenetically morphing tumor cells, can be anticipated to
respond uniformly to a directly targeted nanosystem
approach regardless of the tumor type. As with other
anti-angiogenesis therapies, αvβ3-Dxtl-PD NP treatment will best be used as an adjuvant combined with
effective chemotherapy rather than standalone monotherapy. Further, MR molecular imaging, which was
used in this study to assess anti-angiogenesis response, is a robust technique amenable to identifying
patient populations most likely to have the greatest
treatment benefit-to-risk ratio and longitudinally
monitor for recurrence, but it may lack the sensitivity
required to detect biologically relevant microscopic
levels of neovascularity that may indicate a complete
therapeutic response.
In the present study, the concept and efficacy of
using docetaxel as an Sn 2 lipase labile prodrug was
studied and demonstrated in vitro and in vivo. In contradistinction to the original failed pilot studies pursued with αvβ3-paclitaxel (free) NP, the use of Dxtl-PD
NPs resulted in significant anti-angiogenesis. Further,
Abraxane® given in equivalent doses following the
same treatment regimen was ineffective, emphasizing
the importance of the targeted drug delivery paradigm. Whereas some effective nanomedicine applicahttp://www.thno.org

Theranostics 2014, Vol. 4, Issue 6
tions are intended to be improved excipients,
providing more extended drug release in circulation,
αvβ3-Dxtl-PD NP is an anti-angiogenesis agent that
concentrates a small amount of systemically administered taxane directly on the target for a highly potent effect.

Conclusion
The synthesis of the Sn 2 docetaxel prodrug was
accomplished, which produced a lipophilic prodrug
incorporated into the phospholipid surfactant of PFC
nanoparticles. In endothelial cell culture, the biopotency of paclitaxel, docetaxel, paclitaxel prodrug and
docetaxel prodrug were equivalent. In vitro experiments confirm that the drug was stable in the particle
membrane in plasma and whole blood, even in the
presence of excess phospholipase. Prodrug-laden
particles were bound to target cells, the docetaxel
prodrug was delivered and equivalently bioactive to
the parent drug in the same nanosystem. In the Vx2
cancer model, αvβ3-Dxtl-PD NP elicited strong anti-angiogenesis effects as assessed by MR neovascular
molecular imaging and histopathology, but acute
changes in tumor volumes were not appreciated. In
contradistinction to current anti-angiogenic treatments, for which the intent to blockade or modulate
tumor production of VEGF can be circumvented or
ameliorated by countering biochemical mechanisms
in the epigenetically morphing tumor cells,
αvβ3-Dxtl-PD NP should deliver uniform anti-angiogenic results regardless of the molecular
mechanism of neovessel stimulation and may be an
effective adjuvant to chemotherapies in aggressive
cancers dependent on an expanding rich neovasculature.

Supplementary Material
Additional File 1:
Supplemental Figure 1-Figure 6.
http://www.thno.org/v04p0565s1.pdf

Abbreviations
PFC: perfluorocarbon
CFDD: contact-facilitated drug delivery
API: active pharmaceutical ingredient
Dxtl-PD: docetaxel prodrug
MR(I): magnetic resonance (imaging)
DCC: dicyclohexyl carbodiimide
DMAP: dimethylaminopyridine
PCl5: phosphorous pentachloride
EDCI: 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide
NMR: nuclear magnetic resonance
ESI MS: electron spin ionization mass spectrometry
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PAz-PC: 1-palmitoyl-2-azelaoyl PC, Azelaoyl PC
or 1-O-hexadecanoyl-2-O-(9-carboxyoctanoyl)-snglyceryl-3-phosphocholine
Gd-DOTA: gadolinium 1,4,7,10-tetraazacyclodo
decane-1,4,7,10-tetraacetic acid
Gd-DTPA: gadolinium diethylenetriaminepenta
acetic
TLC: thin layer chromatography
NP: nanoparticle
DLS: dynamic light scattering
Zeta: zeta / electrophoretic potential
TEM: transmission electron microscopy
Sn 2: glycerophospholipids use "sn" notation,
stereospecific numbering. By convention the hydroxyl
group of the second carbon of glycerol (Sn 2) is on the
left on a Fischer projection.
PECAM: platelet endothelial cell adhesion molecule
Tie-2: endothelium-specific receptor tyrosine
kinase
MWCO: molecular weight cut-off
HPLC: high performance liquid chromatography
PEG: polyethylene glycol
DMEM: Dulbecco’s Modified Eagle’s Medium
MTT: colorimetric assay that measures the
reduction of yellow 3-(4,5-dimethythiazol-2-yl)-2,5-di
phenyl tetrazolium bromide (MTT) by mitochondrial
succinate dehydrogenase
DMSO: dimethyl sulfoxide
NAD(P)H: nicotinamide adenine dinucleotide
phosphate (reduced)
SENSE: sensitivity encoding for fast MRI
ROI: region-of-interest
OCT: optimal cutting temperature
PCNA: proliferating cell nuclear antigen
HUVEC: human vascular endothelial cell
PBS: phosphate buffered saline
PLA2: phospholipase A2
VEGF: vascular endothelial growth factor
TKI: Tyrosine kinase inhibitors
PI3K: Phosphatidylinositol 3-kinase
AKT: Protein Kinase B
mTOR: mammalian target of rapamycin
mTORC1: mammalian target of rapamycin
complex 1
mTORC2: mammalian target of rapamycin
complex 2
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